Answers are grounded in this paper and cite their sources.
Although the landscape of migraine symptomatic treatment has been enriched by novel effective drugs, it is mandatory to critically reappraise older molecules to ascertain whether they could still represent reliable alternatives in specific endophenotypes of patients or migraine attacks. Among these, dihydroergotamine (DHE) nasal spray has been shown to be effective and is characterized by greater tolerability and manageability than the parenteral DHE formulation.
No takes yet. Share an insight, caveat, or question.
Silvestro et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: